HMOX1 and hematologic disorder: Though it is emerging as a novel therapeutic target in hematological malignancies [54, 55], the effect of HO1 inhibitor on ROS production (Fig. 6h) needs to be noticed partially as a result of detrimental effect caused by heme metabolites or iron accumulation [50, 53, 56].